Recurrent or Progressive Malignant Glioma Clinical Trial
Official title:
A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma
Verified date | July 2014 |
Source | Angiochem Inc |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
This is a phase 1, multi-centre, sequential cohort, open-label, dose-escalation study of the safety, tolerability, and PK of ANG1005 in patients with recurrent or progressive malignant glioma. ANG1005 will be given by IV infusion once every 21 days (1 treatment cycle). Each patient will participate in only 1 dose group and will receive up to 6 cycles of treatment provided there is no evidence of tumor progression, there is recovery to ≤Grade 1 or baseline nonhematologic, ANG1005-related toxicity (except alopecia), the absolute neutrophil count is ≥1.5 x 109/L, and the platelet count is ≥100 x 109/L.
Status | Completed |
Enrollment | 63 |
Est. completion date | March 2010 |
Est. primary completion date | March 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Written informed consent 2. Histologically confirmed malignant glioma 3. Radiologically confirmed progression of malignant glioma 4. Patients must, in the opinion of the investigator, be ineligible for current standard of care treatment 5. No evidence of acute intracranial/intratumoral hemorrhage 6. Male and female patients 7. Age =18 years 8. Eastern Cooperative Oncology Group (ECOG) performance status 0-2 9. An expected survival of at least 3 months 10. Measurable disease according to Macdonald response criteria 11. Male and female subjects who are not surgically sterile or post-menopausal must agree to use reliable methods of birth control for the duration of the study and for 90 days after the last dose of study drug administration; male partners of female subjects should use condoms for the duration of the study, and for 90 days after the last dose of study drug administration Exclusion Criteria: 1. Chemotherapy, radiotherapy (except palliative radiation delivered to <20% of bone marrow), or investigational agents within 4 weeks before the first dose of study drug. Biologic therapy (such as 13-cis-retinoic acid, thalidomide, tamoxifen, celebrex, erlotinib, imatinib, vorinostat, and lapatinib) and immunotherapy (such as interferon a or b, cdx-110 (EGFR vIII vaccine), interleukin 2, thalidomide) within 1 week before the first dose of study drug. Bevacizumab within 6 weeks before the first dose of study drug 2. Pregnant or lactating females 3. Any acute viral, bacterial, or fungal infection that requires parenteral therapy within 14 days prior to study treatment 4. Known severe hypersensitivity to paclitaxel 5. Severe toxicity with previous taxane treatment 6. Patients being treated with P450 CYP 3A4 or CYP 2C8 enzyme-inducing anti-convulsant drugs within 14 days prior to treatment with study drug 7. Patients with inadequate hematological, liver, and renal function 8. Known or suspected acute or chronic active Hepatitis B, or Hepatitis C or HIV/AIDS 9. Patients with unstable or uncompensated respiratory, cardiac, hepatic or renal disease or any other organ system dysfunction, medical condition, or laboratory abnormality which, in the opinion of the investigator, would either comprise the patient's safety or interfere with the evaluation of the test material 10. Evidence of persistent Grade 2 or greater neurotoxicity |
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label
Country | Name | City | State |
---|---|---|---|
United States | Dana Farber Cancer Institute | Boston | Massachusetts |
United States | University of Virginia Health System | Charlottesville | Virginia |
United States | Henry Ford Health System | Detroit | Michigan |
United States | University of Texas, MD Anderson Cancer Center | Houston | Texas |
United States | Irving Comprehensive Cancer Center, Columbia University Medical Center | New York | New York |
United States | UT Health Science Center at the Cancer Therapy and Research Center (CTRC) | San Antonio | Texas |
Lead Sponsor | Collaborator |
---|---|
Angiochem Inc |
United States,
Drappatz J, Brenner A, Wong ET, Eichler A, Schiff D, Groves MD, Mikkelsen T, Rosenfeld S, Sarantopoulos J, Meyers CA, Fielding RM, Elian K, Wang X, Lawrence B, Shing M, Kelsey S, Castaigne JP, Wen PY. Phase I study of GRN1005 in recurrent malignant glioma — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To characterize the safety and tolerability of intravenously administered ANG1005 in patients with malignant glioma. | On-going | Yes | |
Primary | To identify the maximum tolerated dose (MTD) of ANG1005 in patients with malignant glioma. | End of dose escalation | Yes | |
Secondary | To examine the pharmacokinetics (PK) of ANG1005. | End of study | No | |
Secondary | To confirm the safety and tolerability of ANG1005 at the MTD. | End of dose escalation | Yes | |
Secondary | To assess the immunogenicity of ANG1005. | End of study | No | |
Secondary | To obtain preliminary information about the antitumor activity of ANG1005 in patients with malignant glioma. | On-going | No | |
Secondary | To obtain preliminary information about whether or not ANG1005 crosses the blood- brain barrier into malignant glioma tumors (Sub-study). | On-going | No |